Liz Barrett, UroGen Pharma CEO (Photo by Steven Ferdman/Getty Images)
July 27, 2023 09:55 AM EDTUpdated 01:18 PM
Financing

Uro­Gen nabs $120M to sup­port po­ten­tial 2024 NDA fil­ing, launch of blad­der can­cer chemo gel

Kyle LaHucik

Senior Reporter

Uro­Gen Phar­ma’s hy­dro­gel for­mu­la­tion of a decades-old can­cer drug met the pri­ma­ry end­points in two Phase III tri­als of a sub­set …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

No­vo Nordisk to phase out its pro­duc­tion of hu­man in­sulin pens glob­al­ly

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times